Wave Life Sciences (NASDAQ:WVE) stock surged 5.81% on Tuesday, outperforming the broader market, fueled by the company's impressive fourth-quarter financial results.
The biopharmaceutical company reported a surprise profit of $0.17 per diluted share for the fourth quarter, surpassing analysts' expectations of a $0.19 loss per share. This marked a significant turnaround from the $0.15 loss per share in the year-ago quarter.
Additionally, Wave Life Sciences' revenue for the quarter soared to $83.7 million, up a staggering 188% year-over-year and significantly higher than the consensus estimate of $28.04 million. The strong revenue growth was likely a key driver behind the company's ability to swing to a profit during the quarter.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。